Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48 vs 72 weeks of peginterferon alfa-2a + ribavirin + amantadine in chronic hepatitis C relapse patients
2005-001207-19Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jul 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a, ribavirin and amantadine in hepatitis C virus infection (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Relapse rate. Started Jul 2005; status: completed.
02
Drugs
peginterferon alfa-2aribavirinamantadine
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-001207-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001207-19.